Other Events ·
GSK announced positive registrational data from the phase I/II ARROS-1 trial evaluating Jideytro (zidesamtinib) in…
GLAXFGSK plc
GSK announced positive registrational data from the phase I/II ARROS-1 trial evaluating Jideytro (zidesamtinib) in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer. The study reported a 94% objective response rate and 90% progression-free survival at 12 months, with 70% of patients having measurable brain metastases achieving complete clearance. These results support a planned supplemental New Drug Application to the US FDA in 2026 to expand Jideytro's indication to first-line treatment. GSK operates as a global biopharmaceutical company focused on vaccines, specialty medicines, and consumer healthcare.